DECisive Intracoronary Physiology and Imaging in ACS Non-culprit Lesion Evaluation NCT07548554
Summary
NCT07548554 is an observational clinical trial registered on April 23, 2026, evaluating intracoronary physiology and imaging techniques for assessing and reclassifying non-culprit lesions in patients with acute coronary syndromes. The study examines coronary artery disease using fractional flow reserve and optical coherence tomography under conditions including coronary artery disease, ACS, OCT, and FFR. As an observational registry entry, this trial does not impose compliance obligations on healthcare providers or institutions.
“Current guidelines recommend that decisions regarding revascularization of intermediate epicardial lesions should be based on IIP.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NCT07548554 was added to the ClinicalTrials.gov registry as an observational study examining the use of intracoronary physiology and imaging modalities—specifically fractional flow reserve and optical coherence tomography—in the evaluation of non-culprit lesions among acute coronary syndrome patients. The trial is registered as observational with no specified intervention arms, reflecting a diagnostic assessment study design.
Healthcare institutions and clinical investigators should note that this registry entry represents a research activity rather than a regulatory requirement or compliance mandate. The trial's findings may inform future guideline recommendations regarding the use of invasive intracoronary physiology for intermediate lesion assessment, but no immediate operational changes are required based on this registration alone.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DECisive Intracoronary PHysiology and Imaging in the Evaluation and Reclassification of Non-culprit Lesions in Acute Coronary Syndrome
Observational NCT07548554 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
Despite all advances in diagnostic and therapeutic methods over the past century, ischemic heart disease (IHD) remains a leading cause of mortality and morbidity worldwide. IHD develops as a result of reversible or irreversible impairment of myocardial perfusion in acute or chronic settings. This perfusion abnormality most commonly arises from compromise of epicardial coronary artery patency due to stenosis, occlusion, or vasomotor abnormalities. Structural and/or functional alterations in the microcirculation may also contribute to impaired myocardial perfusion.
Conditions in which myocardial perfusion is acutely compromised are classified as acute coronary syndromes (ACS), whereas reversible ischemia developing on a chronic basis is evaluated under the umbrella of chronic coronary syndromes (CCS). In the assessment of epicardial (macrovascular) or microvascular pathologies leading to ischemia in CCS, angiography, a macroscopic lumenographic method, is often insufficient. Intracoronary pressure and flow measurements are required to determine the impact of angiographically detected epicardial lesions on coronary blood flow, perfusion pressure, and consequently myocardial perfusion. These measurements are referred to as invasive intracoronary physiology (IIP).
Current guidelines recommend that decisions regarding revascularization of intermediate epicardial lesions should be based on IIP. Revascularization guided by IIP is associated with reduced mortality and morbidity, ...
Conditions: Coronary Artery Disease, Acute Coronary Syndromes (ACS), Optic Coherence Tomography, Fractional Flow Reserve
Interventions: Intracoronary Physiology, Intracoronary imaging
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.